Comparative Pharmacology
Head-to-head clinical analysis: AMPHOTEC versus NATACYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPHOTEC versus NATACYN.
AMPHOTEC vs NATACYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death.
Natamycin is a polyene antifungal that binds to ergosterol in fungal cell membranes, increasing permeability and causing cell death.
Initial dose: 0.5 mg/kg intravenously once daily, titrated as tolerated to 5 mg/kg once daily.
One drop of 5% ophthalmic suspension into the conjunctival sac every 1-2 hours for 48 hours, then taper to one drop 4-6 times daily.
None Documented
None Documented
Terminal half-life: 24-48 hours (up to 7 days in hepatic impairment). Long half-life allows once-daily dosing.
Not well characterized due to minimal systemic absorption; estimated to be 2-3 hours in plasma if absorbed.
Biliary/fecal: ~90% unchanged; renal: <10% (mainly as metabolite).
Primarily fecal via biliary elimination; less than 5% renal excretion of absorbed dose.
Category C
Category C
Antifungal
Antifungal, Ophthalmic